Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

ALLO
Allogene Therapeutics, Inc. Common Stock
stock NASDAQ

At Close
May 15, 2025 3:59:36 PM EDT
1.09USD+13.875%(+0.13)4,399,145
1.04Bid   1.10Ask   0.06Spread
Pre-market
May 15, 2025 9:05:30 AM EDT
0.9560USD+0.336%(+0.0032)23,825
After-hours
May 15, 2025 4:52:30 PM EDT
1.05USD-3.226%(-0.04)34,865
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 26, 2022
08:30AM EST  Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced that management plans to participate in four upcoming virtual investor conferences.   GlobeNewswire Inc
Jan 11, 2022
08:19AM EST  Allogene Therapeutics Announces Exclusive Collaboration, Global License Agreement With Antion Biosciences For Multiplex miCAR Technology; Terms Not Disclosed   Benzinga
08:00AM EST  -- miCAR Platform Enables Simultaneous Silencing of Multiple Gene Targets -- Allogene to Deploy miCAR and other Technologies to Create the Next Generation of Allogeneic Cell Products   GlobeNewswire Inc
Jan 10, 2022
09:15PM EST  Cellectis said its licensed partner, Allogene Therapeutics Inc. (ALLO) announced that the U.S. Food and Drug Administration has lifted the clinical hold on its cancer drug trial.   RTTNews
04:33PM EST  Cellectis' Licensed Partner, Allogene Therapeutics, Announces Removal Of FDA Clinical Hold On Their Clinical Trials   Benzinga
04:30PM EST  Allogene reported that Chromosomal Abnormality Was Not the Result of TALEN Gene Editing or Allogenes Manufacturing Process   GlobeNewswire Inc
08:31AM EST  Allogene Therapeutics Reports Removal Of FDA Clinical Hold Across All AlloCAR T Trials   Benzinga
08:30AM EST  Allogene Therapeutics Announces Removal of FDA Clinical Hold   GlobeNewswire Inc
Jan 4, 2022
08:30AM EST  Allogene Therapeutics to Present at the Virtual 40th Annual J.P.   GlobeNewswire Inc
Dec 15, 2021
08:30AM EST  Allogene Therapeutics Expands Headquarters to Support Company   GlobeNewswire Inc
Dec 14, 2021
02:51PM EST  CRISPR Therapeutics Shares Move Higher; Elon Musk, Responding To Gene Editing Article, Says 'This is the revolution in medicine'   Benzinga
07:17AM EST  RBC Capital Maintains Outperform on Allogene Therapeutics, Lowers Price Target to $35   Benzinga
Dec 13, 2021
11:00AM EST  Allogene Therapeutics Reports Positive Results from Phase 1   GlobeNewswire Inc
10:34AM EST  Allogene Therapeutics Reports Positive Phase 1 Data From ALPHA Trials In Non-Hodgkin's Lymphoma At ASH 2021 Meeting   Benzinga
10:30AM EST  Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA   GlobeNewswire Inc
Dec 12, 2021
04:56PM EST  The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More   Benzinga
Dec 1, 2021
08:30AM EST  -- Conference Call and Webcast Scheduled for Monday, December 13, 2021 at 1:30 PM PT/4:30 PM ET   GlobeNewswire Inc
Nov 12, 2021
08:30AM EST  Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced that management plans to participate in five upcoming virtual investor conferences.   GlobeNewswire Inc
Nov 5, 2021
09:27AM EDT  Allogene Therapeutics Sees FY21 GAAP Operating Expenses $300M-$330M   Benzinga
09:27AM EDT  Allogene Therapeutics Q3 EPS $(0.57) Misses $(0.56) Estimate   Benzinga
Nov 4, 2021
08:19AM EDT  The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO   Benzinga
05:00AM EDT  Earnings Scheduled For November 4, 2021   Benzinga
Nov 1, 2021
04:57PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Allogene Therapeutics, Inc. (Allogene or the Company) (NASDAQ:ALLO). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 28, 2021
08:30AM EDT  Allogene Therapeutics to Report Third Quarter Financial Results on   GlobeNewswire Inc
Oct 12, 2021
12:25PM EDT  What 5 Analyst Ratings Have To Say About Allogene Therapeutics   Benzinga
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
08:02AM EDT  JMP Securities Maintains Market Outperform on Allogene Therapeutics, Lowers Price Target to $27   Benzinga
Oct 11, 2021
03:18PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Allogene Therapeutics, Inc. (Allogene or the Company) (NASDAQ:ALLO). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Oct 10, 2021
11:59AM EDT  The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations and IPOs Take Center Stage   Benzinga
Oct 8, 2021
02:36PM EDT  Mid-Afternoon Market Update: Dow Surges 80 Points; ChemoCentryx Shares Spike Higher   Benzinga
12:30PM EDT  Mid-Day Market Update: Crude Oil Rises 2%; Allogene Therapeutics Shares Plunge   Benzinga
12:11PM EDT  Where Allogene Therapeutics Stands With Analysts   Benzinga
11:52AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 8, 2021   Benzinga
11:33AM EDT  UPDATE: RBC Capital On Allogene Price Target Cut: Firm Warns On FDA Hold Following Detection Of Chromosomal Abnormality Following Clinical Trials; Sees Multiple Confounding Factors Given Current Findings Still Present Minimal To No Clinical Significance   Benzinga
11:01AM EDT  Shares of Allogene Therapeutics, Inc. (ALLO) are tanking over 40% on Friday morning after the U.S. Food and Drug Administration put a clinical hold on the clinical-stage biotech company's cancer drug trial.   RTTNews
10:11AM EDT  Mid-Morning Market Update: Markets Edge Higher; US Economy Adds 194,000 Jobs In September   Benzinga
09:11AM EDT  10 Biggest Price Target Changes For Friday   Benzinga
07:54AM EDT  Stifel Downgrades Allogene Therapeutics to Hold   Benzinga
07:18AM EDT  RBC Capital Maintains Outperform on Allogene Therapeutics, Lowers Price Target to $45   Benzinga
06:51AM EDT  The following are some of the stocks making big moves in Friday's pre-market trading (as of 6.30 A.M. EDT).   RTTNews
06:28AM EDT  Goldman Sachs Downgrades Allogene Therapeutics to Neutral, Lowers Price Target to $20   Benzinga
Oct 7, 2021
05:17PM EDT  Shares of Allogene Therapeutics, Inc. (ALLO) tanked over 40% in extended trading session on Thursday after the U.S. Food and Drug Administration put a clinical hold the clinical-state biotech company's cancer drug trial.   RTTNews
04:22PM EDT  Allogene Shares To Resume Trade At 4:45 p.m. EDT   Benzinga
04:17PM EDT  UPDATE: Allogene Notes Co. 'Believes Data from the ALPHA Trials Demonstrates a Favorable Clinical Profile of ALLO-501A'   Benzinga
04:16PM EDT  UPDATE: Allogene Says 'Testing in a Patient with Low Blood Counts Showed a Chromosomal Abnormality in ALLO-501A CAR T Cells of Unclear Clinical Significance; Patient Achieved a Partial Response to Therapy'   Benzinga
04:15PM EDT  Allogene Reports FDA Clinical Hold Of AlloCAR T Trials, Cites Single Patient Case   Benzinga
04:15PM EDT  Allogene Therapeutics Reports FDA Clinical Holdof   GlobeNewswire Inc
04:13PM EDT  Allogene Shares Halted, News Pending   Benzinga
Sep 24, 2021
10:43AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021   Benzinga
04:49AM EDT  Raymond James Upgrades Allogene Therapeutics to Outperform, Announces $36 Price Target   Benzinga
Sep 20, 2021
08:30AM EDT  Allogene Therapeutics Adds Renowned CAR T Expert, Jae Park, M.D.   GlobeNewswire Inc
Sep 1, 2021
08:30AM EDT  Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced that management plans to participate in two upcoming virtual investor conferences.   GlobeNewswire Inc
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 12, 2021
12:32PM EDT  Allogene shares were trading higher after the company received FDA Orphan Drug Designation for ALLO-715.   Benzinga
11:06AM EDT  Allogene's BCMA-Targeted Therapy Gets US Orphan Drug Tag For Multiple Myeloma   Benzinga
08:31AM EDT  Allogene Reports Receives FDA Orphan Drug Designation For ALLO-715 For Treatment Of Multiple Myeloma   Benzinga
08:30AM EDT  Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD)   GlobeNewswire Inc
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Aug 4, 2021
04:52PM EDT  Allogene Therapeutics Q2 EPS $(0.53) Beats $(0.55) Estimate, Sales $44.00K   Benzinga
04:02PM EDT  Allogene Therapeutics Reports Second Quarter 2021 Financial Results   GlobeNewswire Inc
04:10AM EDT  Earnings Scheduled For August 4, 2021   Benzinga
Aug 2, 2021
08:43AM EDT  Allogene Therapeutics Appoints Elizabeth Barrett And Vicki Sato To Board   RTTNews
08:30AM EDT  Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz)   GlobeNewswire Inc
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 14, 2021
07:48AM EDT  The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues   Benzinga
Jul 12, 2021
08:30AM EDT  Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced that management plans to participate in two upcoming virtual investor conferences.   GlobeNewswire Inc
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jun 30, 2021
08:33AM EDT  Allogene Therapeutics Granted FDA Fast Track Designation For ALLO-605, A TurboCAR T Cell Therapy, For The Treatment Of Relapsed/Refractory Multiple Myeloma   Benzinga
08:30AM EDT  -- Phase 1 IGNITE Dose Escalation Trial of ALLO-605 Initiated in Q2 2021 -- ALLO-605 is the Third Prong of the Companys Clinical Strategy to Target BCMA for the Treatment of Multiple Myeloma -- TurboCARTM Technology Provides Selective, Programmable Cytokine Signaling Designed to Improve Function and Potency of AlloCAR TCells   GlobeNewswire Inc
Jun 24, 2021
08:12AM EDT  The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO   Benzinga
Jun 21, 2021
07:06AM EDT  Allogene Overland Biopharm Appoints Shuyuan Yao As CEO   RTTNews
07:00AM EDT  Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive Officer   Business Wire
Jun 8, 2021
09:17AM EDT  The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex   Benzinga
Jun 4, 2021
09:39AM EDT  The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact   Benzinga
09:09AM EDT  Allogene Therapeutics Highlights Phase 1 Data On ALLO-501 And ALLO-501A In Relapsed/Refractory Non-Hodgkin Lymphoma At 2021 ASCO Meeting   Benzinga
09:00AM EDT  Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501   GlobeNewswire Inc
May 26, 2021
07:33AM EDT  The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing   Benzinga
May 20, 2021
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2021   Benzinga
08:30AM EDT  Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced that management plans to participate in five upcoming virtual investor conferences.   GlobeNewswire Inc
08:27AM EDT  The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks   Benzinga
08:02AM EDT  Truist Securities Upgrades Allogene Therapeutics to Buy, Raises Price Target to $41   Benzinga
May 19, 2021
04:52PM EDT  Allogene Therapeutics Highlights Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021   Benzinga
04:52PM EDT  Allogene Therapeutics CD19 Forum Highlights Positive Results from   GlobeNewswire Inc
May 14, 2021
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 14, 2021   Benzinga
06:26AM EDT  B. Riley Securities Initiates Coverage On Allogene Therapeutics with Buy Rating, Announces Price Target of $52   Benzinga
May 12, 2021
08:30AM EDT  Allogene Therapeutics to Host Virtual CD19 Forum on May 19, 2021   GlobeNewswire Inc
May 5, 2021
04:27PM EDT  Allogene Therapeutics Q1 EPS $(0.25) Beats $(0.46) Estimate, Sales $38.34M Beat $13.92M Estimate; Sees FY21 GAAP Opex $300M-$330M   Benzinga
04:02PM EDT  Allogene Therapeutics Reports First Quarter 2021 Financial   GlobeNewswire Inc
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
04:16AM EDT  Earnings Scheduled For May 5, 2021   Benzinga
Apr 28, 2021
09:33AM EDT  Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology   Benzinga
09:24AM EDT  Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR   GlobeNewswire Inc
Apr 27, 2021
08:30AM EDT  Allogene Therapeutics to Report First Quarter Financial Results on   GlobeNewswire Inc
Apr 21, 2021
08:37AM EDT  Allogene Therapeutics Announces FDA Regenerative Medicine Advanced Therapy Designation Granted To ALLO-715, An AlloCAR T Cell Therapy In Development For Relapsed/Refractory Multiple Myeloma   Benzinga
08:37AM EDT  -- RMAT Designation Follows Proof-of-Concept Data from ALLO-715 UNIVERSAL Trial in Heavily Pretreated, Refractory Multiple Myeloma Patients -- UNIVERSAL Trial Demonstrated for the First Time that an Allogeneic CAR T Therapy Directed at BCMA Can Achieve Clinical Responses While Eliminating the Need for Bridging Therapy or Delays in Treatment Associated with Manufacturing   GlobeNewswire Inc
Apr 19, 2021
08:39AM EDT  Allogene Therapeutics Says Receives IND Clearance From FDA For ALLO-605 For The Treatment Of Patients With Relapsed/Refractory Multiple Myeloma   Benzinga
08:30AM EDT  -- TurboCAR Technology Allows a Programmable Cytokine Signaling to Potentially Control T Cell Exhaustion and Improve Function and Potency of AlloCAR TCells -- Phase 1 IGNITE Trial Expected to Begin in Mid-2021 -- ALLO-605 is One of Allogenes Three Strategies to Target BCMA for the Treatment of Patients with Multiple Myeloma   GlobeNewswire Inc
Apr 12, 2021
10:26AM EDT  Allogene Therapeutics Saturday Morning Announced Preclinical Research Highlighting Novel TurboCAR T Cell Technology Designed To Overcome Immune Suppression In Solid Tumors At American Association For Cancer Research Conference   Benzinga
08:33AM EDT  Allogene Therapeutics, SpringWorks Therapeutics Report Dosing Of First Patient In Phase 1 Study Evaluating ALLO-715 In Combo With Nirogacestat In Patients With Relapsed, Refractory Multiple Myeloma   Benzinga
08:30AM EDT  Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing   GlobeNewswire Inc
Apr 10, 2021
08:30AM EDT  Allogene Therapeutics Presents Preclinical Research Highlighting a   GlobeNewswire Inc
Mar 1, 2021
07:04AM EST  HC Wainwright & Co. Maintains Buy on Allogene Therapeutics, Raises Price Target to $43   Benzinga
Feb 25, 2021
04:28PM EST  Allogene Therapeutics Q4 EPS $(0.53) Beats $(0.56) Estimate   Benzinga
08:08AM EST  The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants   Benzinga
04:03AM EST  Earnings Scheduled For February 25, 2021   Benzinga
Feb 18, 2021
08:30AM EST  Allogene Therapeutics to Report Fourth Quarter and Full Year 2020   GlobeNewswire Inc
Feb 9, 2021
08:30AM EST  Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced that management plans to participate in four upcoming virtual investor conferences.   GlobeNewswire Inc
Jan 26, 2021
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2021   Benzinga
08:30AM EST  -- Prestigious Prize Presented to Distinguish Leading-Edge Researchers in Europe -- Dr. Schumacher Recognized for the Development of Technologies to Study the Role of the Immune System in Cancer Progression and for the Improvement of Cancer Diagnosis and Treatment   GlobeNewswire Inc
07:03AM EST  Stifel Upgrades Allogene Therapeutics to Buy, Raises Price Target to $43   Benzinga
Jan 5, 2021
08:30AM EST  Allogene Therapeutics to Present at the Virtual 39th Annual J.P.   GlobeNewswire Inc
Dec 23, 2020
11:30AM EST  Allogene Therapeutics Receives IND Clearance From U.S. FDA For ALLO-715 In Combination With Nirogacestat In Relapsed/Refractory Multiple Myeloma   Benzinga
11:30AM EST  -- Combination Represents One of Allogenes Three Strategies to Target BCMA for Multiple Myeloma -- Phase 1 Clinical Trial Expected to Begin in the First Quarter of 2021   GlobeNewswire Inc
Dec 15, 2020
06:10AM EST  Allogene Therapeutics And Overland Form JV To Develop And Commercialize AlloCAR T Cell Therapies   RTTNews
06:08AM EST  Allogene Therapeutics And Overland Pharmaceuticals Form Joint Venture in Greater China To Develop And Commercialize AlloCAR T Cell Therapies; Overland To Make $40M Upfront Payment And Invest $77M In Capital To Support Operations   Benzinga
06:00AM EST  Allogene Therapeutics and Overland Pharmaceuticals Form Joint   GlobeNewswire Inc
Dec 10, 2020
06:26AM EST  HC Wainwright & Co. Assumes Allogene Therapeutics at Buy, Announces Price Target of $40   Benzinga
Dec 7, 2020
10:25AM EST  Allogene Therapeutics Presents Preclinical Findings Supporting ALLO-605 At ASH 2020   Benzinga
10:00AM EST  -- ALLO-605 Demonstrated Enhanced Killing of Multiple Myeloma Cells and Persistence Relative to BCMA CAR T -- TurboCAR Technology Represents a Key Component to the Companys Three-Pronged Clinical Strategy Targeting BCMA for Multiple Myeloma -- Investigational New Drug (IND) Application for ALLO-605 Expected in the First Half of 2021   GlobeNewswire Inc
Dec 6, 2020
10:00AM EST  Allogene Therapeutics Presents Preclinical Data on ALLO-316 in   GlobeNewswire Inc
Dec 5, 2020
01:15PM EST  Allogene Therapeutics Announced Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma at ASH 2020   Benzinga
12:30PM EST  Allogene Therapeutics Reports Positive Initial Results from Phase   GlobeNewswire Inc
Dec 2, 2020
08:30AM EST  Allogene Therapeutics Announces Webinar to Review Initial ALLO-715   GlobeNewswire Inc
Nov 29, 2020
08:59AM EST  The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions   Benzinga
Nov 12, 2020
08:30AM EST  Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced that management plans to participate in four investor conferences through the end of the year.   GlobeNewswire Inc
Nov 4, 2020
10:24AM EST  Mid-Morning Market Update: Markets Open Higher; Performance Food Earnings Top Views   Benzinga
09:08AM EST  Allogene Therapeutics Announces Oral Presentation Of Initial Results From Phase 1 Dose Escalation Study Of ALLO-715 In Relapsed/Refractory Multiple Myeloma On Dec. 5   Benzinga
09:03AM EST  Allogene Therapeutics Announces Oral Presentation of Initial   GlobeNewswire Inc
07:42AM EST  Allogene Therapeutics Sees FY20 GAAP Net Loss $280M-$260M   Benzinga
07:33AM EST  Allogene Therapeutics Q3 EPS $(0.52) Beats $(0.54) Estimate   Benzinga
07:30AM EST  Allogene Therapeutics Reports Third Quarter 2020 Financial Results   GlobeNewswire Inc
04:41AM EST  Earnings Scheduled For November 4, 2020   Benzinga
Oct 27, 2020
08:30AM EDT  Allogene Therapeutics to Report Third Quarter 2020 Financial   GlobeNewswire Inc
Oct 23, 2020
10:48AM EDT  Benzinga's Top Upgrades, Downgrades For October 23, 2020   Benzinga
06:01AM EDT  RBC Capital Initiates Coverage On Allogene Therapeutics with Outperform Rating, Announces Price Target of $55   Benzinga
Oct 15, 2020
08:06AM EDT  Allogene Therapeutics, MD Anderson Announce Strategic Collaboration To Accelerate Advancement Of Allogeneic CAR T Therapy   Benzinga
08:00AM EDT  -- Clinical and Translational Research Collaboration Will Evaluate Multiple AlloCAR T Candidates Across the Allogene Portfolio Targeting Multiple Tumor Types   GlobeNewswire Inc
Oct 1, 2020
08:30AM EDT  Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced that management plans to participate in the Jefferies Virtual Cell Therapy Summit in October 2020.   GlobeNewswire Inc
Aug 5, 2020
07:43AM EDT  Allogene Therapeutics Q2 EPS $(0.53) Beats $(0.54) Estimate   Benzinga
07:30AM EDT  Allogene Therapeutics Reports Second Quarter 2020 Financial Results   GlobeNewswire Inc
04:21AM EDT  Earnings Scheduled For August 5, 2020   Benzinga
Jul 28, 2020
08:30AM EDT  Allogene Therapeutics to Report Second Quarter 2020 Financial   GlobeNewswire Inc
Jul 20, 2020
08:33AM EDT  Notch Therapeutics Appoints David Main As President And CEO   RTTNews
08:30AM EDT  to Advance the Company's Novel Gene-Edited, iPSC-Derived Immune Cell Therapeutics   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC